Chairman and CEO of PositiveID (OTCBB: PSID) Discusses Catalysts for 2012 in Diabetes Market and Homeland Security Market
New York, NY- February 16, 2012 – (Investorideas.com Newswire) Medical Technology Stock news alert: Investorideas.com, a leader in research for independent investors presents an exclusive Q&A interview with Medical technology stock, PositiveID Corporation (OTCBB: PSID). Mr. William J. Caragol, Chairman and Chief Executive Officer discusses the catalysts for 2012 for both its diabetes management technologies and its Homeland Security airborne bio-threat detection technology.
Q: Investorideas.com
We noted that late last year the Department of Homeland Security (“DHS”) Office of Health Affairs began the procurement process for the deployment of an autonomous biodetection system called BioWatch Gen-3. Can you give investors insight as to the potential 2012 opportunities for the Company’s airborne bio-threat detection technology (M-BAND) in this process?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
Our MicroFluidic Systems (“MFS”) subsidiary, is a leader in biothreat detection technologies and molecular diagnostic systems, and developed its M-BAND technology under contract from DHS over the past eight years. We believe our M-BAND, a Microfluidics-based Bioagent Autonomous Networked Detector, is one of only two technologies that is compatible with DHS’ procurement for Gen-3 of Biowatch, which has a total value of more than $3 billion over approximately five years, as described by the DHS in their draft RFP. This opportunity, relative to the provision of biodetectors and the renewables, represents a very significant opportunity for PositiveID.
Q: Investorideas.com
With your three diabetes management technologies, Easy Check™, GlucoChip™ and iglucose™, can you give investors a quick summary of some of the recent key developments announced by the Company and some of the key drivers for 2012?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
We continue to make significant progress with each of our diabetes management products. Starting with Easy Check, our non-invasive breath glucose detection device, we completed a prototype device in 2011 and achieved positive preliminary results in early testing that are within industry standards. We recently announced the initiation of a clinical study of Easy Check with Schneider Children’s Medical Center in Israel, led by a world leading endocrinologist. We expect to have results from that study later this year.
Moving on to GlucoChip, a continuous glucose-sensing microchip, we have completed Phase II development and proved a stable and reproducible, closed-cycle continuous glucose sensor that functions in human blood. We also recently provided an update on a biotransport study we are conducting with the Diabetes Research Institute at the University of Miami, which has yielded positive preliminary results. We will continue to provide updates on our progress over the next few months. As those results develop, we will look to work with a partner to incorporate the glucose-sensing system with a micro-electromechanical system signal transduction unit and the electronics of a radio frequency identification microchip to complete development of GlucoChip
Last but not least, we received FDA clearance for iglucose, which is a mobile health system for diabetes management, in late 2011, and are now preparing to roll-out this product with health insurers and home-healthcare providers. As we look ahead to the rest of 2012, we expect that the initial roll-out of iglucose in the first half of the year will be followed by larger orders and partnering agreements.
Q: Investorideas.com
Your technology takes management of diabetes to the clouds literally. With the iglucose technology, the data stored in the diabetes management portal can be shared automatically by text messaging or email. How significant a breakthrough is this for family members, caregivers and healthcare professionals and most importantly, the patient?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
The value proposition of iglucose is to provide an individual with diabetes flexibility and wireless connectivity to better manage their condition and stay in touch with loved ones. With iglucose, an individual no longer has to keep manual logbooks – iglucose automatically pulls the data from a glucometer and sends it to the cloud. Patients can continue to use their preferred blood glucose meter and there is no cell phone or data plan required. iglucose simplifies diabetes management by automating the process of providing blood glucose readings to healthcare professionals for more informed communication and treatment decisions. iglucose also provides peace of mind for family members that their loved ones are testing and what their values are.
Q: Investorideas.com
Easy Check is your non-invasive breath glucose detection device that measures the level of acetone in a patient's exhaled breath and correlates that acetone level to a measure of blood glucose. With a rapid growth of diabetes in children how significant is it to have a technology that could eliminate a patient's need to prick his or her finger multiple times per day to get a blood sugar reading?
A: Mr. William J. Caragol, Chairman and Chief Executive Officer
Being able to provide the diabetes community with a non-invasive method of testing their blood sugar is often called the “Holy Grail” of diabetes management. Certainly for children, offering non-invasive testing is even more important and appealing. Many times, people with diabetes do not test as often as prescribed by their physician due to the pain and inconvenience of drawing blood.
About PositiveID Corporation
PositiveID Corporation develops unique medical devices and molecular diagnostic systems, focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MFS, is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. For more information on PositiveID, please visit www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including the likelihood that its M-BAND is one of only two technologies that is compatible with DHS’ procurement for Gen-3 of Biowatch, which has a total value of more than $3 billion over approximately five years, as described by the DHS in their draft RFP; the likelihood that this opportunity, relative to the provision of biodetectors and the renewables, represents a very significant opportunity for PositiveID; the likelihood that PositiveID will continue to make significant progress with each of its diabetes management products; the likelihood that PositiveID will have results from its Easy Check clinical study later this year; the likelihood that PositiveID will continue to provide updates on its progress with GlucoChip over the next few months; the likelihood that as those results develop, PositiveID will look to work with a partner to incorporate the glucose-sensing system with a micro-electromechanical system signal transduction unit and the electronics of a radio frequency identification microchip to complete development of GlucoChip; the likelihood that PositiveID is now preparing to roll-out this product with health insurers and home-healthcare providers; the likelihood that the initial roll-out of iglucose in the first half of the year will be followed by larger orders and partnering agreements; the likelihood that iglucose simplifies diabetes management by automating the process of providing blood glucose readings to healthcare professionals for more informed communication and treatment decisions; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully complete development and commercialize Easy Check, GlucoChip and iglucose; the likelihood that PositiveID will participate in BioWatch Gen-3; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Contact:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Learn more about PSID at Investorideas.com
http://www.investorideas.com/CO/PSID/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer /Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation (OTCBB:PSID) featured biotech company on Investorideas.com for 3 months effective January 30, 2012. Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and company profile .More info:www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Contact Investorideas.com 800 665 0411
(1) EBIITDA = Earnings before interest, impairment, taxes, depreciation and amortization